Evidence map›Paper›PMID 23409160›Full record

ArticlePloS one2013

Evaluation of silk biomaterials in combination with extracellular matrix coatings for bladder tissue engineering with primary and pluripotent cells.

Debra Franck, Eun Seok Gil, Rosalyn M Adam, David L Kaplan, Yeun Goo Chung, Carlos R Estrada, Joshua R Mauney

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Bioengineering Approaches for Bladder Regeneration.International journal of molecular sciences · 2018
    Review
  10. Stem Cells in Functional Bladder Engineering.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016
    Review
  11. Review
  12. Article
  13. Dynamic reciprocity in cell-scaffold interactions.Advanced drug delivery reviews · 2015
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Debra FranckDepartment of Urology, Urological Diseases Research Center, Boston Children's Hospital, Boston, Massachusetts, United States of America.
Eun Seok Gil
Rosalyn M Adam
David L Kaplan
Yeun Goo Chung
Carlos R Estrada
Joshua R Mauney
Boston Children's Hospital · USHarvard University · USTufts University · US

Funding

Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
Urethral Tissue BioengineeringP50DK065298 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ADAM, ROSALYN M · 2003 to 2012
$9.8M
Novel Strategies in Bladder Tissue Engineering: Stem Cells and Silk BiomaterialsR00DK083616 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI MAUNEY, JOSHUA ROBERT · 2012 to 2014
$639k
Novel Strategies in Bladder Tissue Engineering: Stem Cells and Silk BiomaterialsK99DK083616 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI MAUNEY, JOSHUA ROBERT · 2011 to 2012
$178k
NIBIB NIH HHS P41 EB002520NIDDK NIH HHS K99 DK083616NIDDK NIH HHS K99DK083616-01A2NIDDK NIH HHS P50 DK065298NIDDK NIH HHS R00 DK083616
6 · The paper itself

Abstract

Silk-based biomaterials in combination with extracellular matrix (ECM) coatings were assessed as templates for cell-seeded bladder tissue engineering approaches. Two structurally diverse groups of silk scaffolds were produced by a gel spinning process and consisted of either smooth, compact multi-laminates (Group 1) or rough, porous lamellar-like sheets (Group 2). Scaffolds alone or coated with collagen types I or IV or fibronectin were assessed independently for their ability to support attachment, proliferation, and differentiation of primary cell lines including human bladder smooth muscle cells (SMC) and urothelial cells as well as pluripotent cell populations, such as murine embryonic stem cells (ESC) and induced pluripotent stem (iPS) cells. AlamarBlue evaluations revealed that fibronectin-coated Group 2 scaffolds promoted the highest degree of primary SMC and urothelial cell attachment in comparison to uncoated Group 2 controls and all Group 1 scaffold variants. Real time RT-PCR and immunohistochemical (IHC) analyses demonstrated that both fibronectin-coated silk groups were permissive for SMC contractile differentiation as determined by significant upregulation of α-actin and SM22α mRNA and protein expression levels following TGFβ1 stimulation. Prominent expression of epithelial differentiation markers, cytokeratins, was observed in urothelial cells cultured on both control and fibronectin-coated groups following IHC analysis. Evaluation of silk matrices for ESC and iPS cell attachment by alamarBlue showed that fibronectin-coated Group 2 scaffolds promoted the highest levels in comparison to all other scaffold formulations. In addition, real time RT-PCR and IHC analyses showed that fibronectin-coated Group 2 scaffolds facilitated ESC and iPS cell differentiation toward both urothelial and smooth muscle lineages in response to all trans retinoic acid as assessed by induction of uroplakin and contractile gene and protein expression. These results demonstrate that silk scaffolds support primary and pluripotent cell responses pertinent to bladder tissue engineering and that scaffold morphology and fibronectin coatings influence these processes.

Indexed as

AnimalsBiocompatible MaterialsCell LineEmbryonic Stem CellsExtracellular Matrix ProteinsHumansInduced Pluripotent Stem CellsMiceMyocytes, Smooth MuscleSilkTissue EngineeringTissue ScaffoldsUrinary BladderUrotheliumBiocompatible MaterialsExtracellular Matrix ProteinsSilk

Identifiers

PMID23409160
PMCPMC3567020
OpenAlexW1991832929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.